BiomX Inc.

BiomX Inc., a clinical-stage biopharmaceutical company focused on engineered phage-based therapeutics, completed a business combination with Chardan Healthcare Acquisition Corp, a blank-check vehicle sponsored by Chardan, a New York-based healthcare-focused investment bank. The transaction was announced in March 2024 and has since closed. BiomX develops bacteriophage therapies targeting diseases where the human microbiome plays a central role, with programs spanning dermatology and antibiotic-resistant infections. The deal is classified under the Other and Diversified sector. For complete filing history, deal analytics, and institutional data on this transaction and the broader SPAC universe, sign up for full access at SpacDesk.

SPAC Counterparty (1)